CN103142923B - Compound mongolian medicine preparation for treating coronary heart disease - Google Patents
Compound mongolian medicine preparation for treating coronary heart disease Download PDFInfo
- Publication number
- CN103142923B CN103142923B CN201310096440.7A CN201310096440A CN103142923B CN 103142923 B CN103142923 B CN 103142923B CN 201310096440 A CN201310096440 A CN 201310096440A CN 103142923 B CN103142923 B CN 103142923B
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- preparation
- coronary heart
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a compound mongolian medicine preparation for a treating coronary heart disease. The preparation is prepared from the following raw materials in parts by weight: 7-11 parts of fructus choerospondiatis, 4-8 parts of nutmeg, 4-8 parts of agarwood, 2-6 parts of saffron, 2-6 parts of amomum tsao-ko, 1-5 parts of gardenia, 3-6 parts of radix aucklandiae, 3-6 parts of poria cocos, 3-6 parts of angelica, 3-6 parts of cumin, 1-2 parts of saffron, 1 part of ferula asafetida and 0.5 part of artificial bezoar. The compound mongolian medicine preparation has efficacies of clearing away 'Khii' heat, activating qi and blood and tonifying heart, and is used for treating palpitation, shortness of breath, chest tightness and irritability, especially used for palpitation, chest tightness, dizziness, insomnia, and'Khii'blood phase syndromes.
Description
Technical field
The present invention relates to therapeutic drug of coronary heart disease field, especially, relate to the Mongolian compound preparation being used for the treatment of coronary heart disease.
Background technology
At present, the disease of the three large Disease Center vascular systems of the mankind is threatened to occupy second.People carry out many-sided research, topmost or drug research to capture these diseases.National medicine of capturing for these difficult and complicated illness has potential meaning.Especially, for cardiovascular system diseases, mongolian medicine has good curative effect.In recent years, the incidence trend of coronary heart disease constantly rises, and as can be seen from the data that nineteen ninety national disease detection system obtains, accounts for that the cause of the death is primary surely belongs to cardiovascular disease in urban population.Therefore, to the research of coronary heart disease treatment be the focus be jointly concerned about at present both at home and abroad.
Drug therapy coronary heart disease, adopts coronary dilating, blood fat reducing, anticoagulant, calcium retardance etc., although the effective in cure side effect all had in various degree at present.The traditional Chinese medical science and national coronary heart diseases and angina pectoris of curing have its characteristic.The world today has recognized that chemical synthetic drug can cause a large amount of drug induccd, iatrogenic disease.Today that the cry returning Fructus Cumini Cymini people grows to even greater heights, mongolian medicine development will likely become the focus of world medicine development in future.Its advantage is had capturing chronic, progressivity, invisible disease using total concept as the Mongolia Medicine of marrow.
Summary of the invention
An object of the present invention is to provide a kind of Mongolian compound preparation being used for the treatment of coronary heart disease, it is formed by the preparation of raw material of following weight portion:
Fructus Choerospondiatis 7-11, Semen Myristicae 4-8, Lignum Aquilariae Resinatum 4-8, Flos Carthami 2-6, Fructus Tsaoko 2-6, Fructus Gardeniae 1-5, Radix Aucklandiae 3-6, Poria 3-6, Radix Angelicae Sinensis 3-6, Fructus Cumini Cymini 3-6, Stigma Croci 1-2, Resina Ferulae 1, artificial Calculus Bovis 0.5.
Be preferably: Fructus Choerospondiatis 9, Semen Myristicae 6, Lignum Aquilariae Resinatum 6, Flos Carthami 4, Fructus Tsaoko 8, Fructus Gardeniae 3, the Radix Aucklandiae 4.5, Poria 4.5, Radix Angelicae Sinensis 4.5, Fructus Cumini Cymini 4.5, Stigma Croci 1.5, Resina Ferulae 1, artificial Calculus Bovis 0.5.
The medicine type of compound Mongolian medicinal preparation of the present invention can be powder, the watered pill, drop pill, tablet or capsule etc. prepared by conventional method.
The medicine type of compound Mongolian medicinal preparation of the present invention can be powder, the watered pill, drop pill, tablet or capsule etc. prepared by conventional method.
Fang Xie: this compound preparation mentality of designing and substantially treat heart twinge logos based on Mongolian medicine, selects medicine prescription main points as follows: sweet, the acid of Fructus Choerospondiatis nature and flavor in side and putting down; Effect is heavy, greasy.Nature and flavor and usefulness town " conspicuous according to ", " golden light annotation collection " claims it: " Fructus Choerospondiatis taste, to change taste all sweet, with flavour of a drug doctor disease ..., function clears away heart-fire heat "." book on Chinese herbal medicine " is said again: " Fructus Choerospondiatis for except heart disease will (" Chinese herbaceous peony sand ") ", and " mongolian medicine " is said: " clear away heart-fire heat, heart tonifying ".Semen Myristicae nature and flavor are pungent and warm.Lignum Aquilariae Resinatum in side, Fructus Tsaoko and Resina Ferulae town " conspicuous according to ", pain relieving; Fructus Gardeniae, Flos Carthami ask heat in blood; Calculus Bovis heat-clearing and toxic substances removing, happy key, during Muxiangliqi is adjusted, drying dampness to eliminate phlegm; Poria promoting diuresis to eliminate damp pathogen, invigorating the spleen for dissipating phlegm, mind tranquilizing and the heart calming, relieves internal heat anticancer.Mild in medicine property and, dampness removing and do not hinder healthy energy; Radix Angelicae Sinensis is warm in nature, sweet in the mouth, pungent, returns liver, the heart, spleen channel.To enrich blood the effect such as to invigorate blood circulation; Fructus Cumini Cymini can promoting the circulation of QI to relieve pain, soothing the liver, anti-inflammation of regulating the flow of vital energy; Stigma Croci can treat the multiple chronic disease of human body, by effect of its blood circulation promoting and blood stasis dispelling, anti-inflammation, and enhancing body endurance, strengthen lymphproliferation response, improve Cellular Immunity and humoral immunization with this, play adjustment human functional activity of vital energy and run, the effect of balanced human's negative and positive.Compared with the compound preparation of the treatment coronary heart disease that our and relevant series is applied for, the cold flavour of a drug such as Lignum Santali Albi, Borneolum Syntheticum are deducted, add the nourishing such as the Radix Aucklandiae, Poria, Radix Angelicae Sinensis, Fructus Cumini Cymini, Stigma Croci flavour of a drug to be referred to as " growing the heart to fall apart ", uncomfortable in chest for cardiopalmus, dizzy insomnia, " conspicuous according to " blood rich syndrome mutually.
Detailed description of the invention
Embodiment 1
Raw material is prepared: Fructus Choerospondiatis 7, Semen Myristicae 4, Lignum Aquilariae Resinatum 4, Flos Carthami 2, Fructus Tsaoko 2, Fructus Gardeniae 1, the Radix Aucklandiae 3, Poria 3, Radix Angelicae Sinensis 3, Fructus Cumini Cymini 3, Stigma Croci 1, Resina Ferulae 1, artificial Calculus Bovis 0.5 by following raw material weight proportioning.Pulverized 80 orders, bout is even obtains powder, powder 15g/ bag.
Embodiment 2
Raw material is prepared: Fructus Choerospondiatis 9, Semen Myristicae 6, Lignum Aquilariae Resinatum 6, Flos Carthami 4, Fructus Tsaoko 8, Fructus Gardeniae 3, the Radix Aucklandiae 4.5, Poria 4.5, Radix Angelicae Sinensis 4.5, Fructus Cumini Cymini 4.5, Stigma Croci 1.5, Resina Ferulae 1, artificial Calculus Bovis 0.5 by following raw material weight proportioning.Pulverizing 80 orders, is that the watered pill made according to a conventional method by excipient with yellow wine, every 100 heavy 6g.
Embodiment 3
Raw material is prepared: Fructus Choerospondiatis 11, Semen Myristicae 8, Lignum Aquilariae Resinatum 8, Flos Carthami 6, Fructus Tsaoko 6, Fructus Gardeniae 5, the Radix Aucklandiae 6, Poria 6, Radix Angelicae Sinensis 6, Fructus Cumini Cymini 6, Stigma Croci 2, Resina Ferulae 1, artificial Calculus Bovis 0.5 by following raw material weight proportioning.Pulverized 80 orders, and be prepared into drop pill according to a conventional method, specification is 0.2g/ grain.
Embodiment 4, pharmacodynamic study result
Prove through Pharmacodynamic test of active extract: 1. compound preparation of the present invention can reduce mice oxygen consumption, time-to-live extended period (P<0.05), compare without significant difference with propranolol.Prompting said preparation has maintenance effect to myocardial ischemia; 2. compound preparation of the present invention can improve the myocardial ischemia ECG Change that pituitrin causes, and as T ripple is raised, S-T section is lifted high or low flat (P<0.05, P<0.01).Compare with nitroglycerin, occur that the time of effect is early than nitroglycerin (P<0.05); 3. LDH(lactic acid dehydrogenase in serum) content significantly has and resists myocardial ischemia lower than blank group (P<0.01, P<0.05) prompting, protecting myocardial cell effect.After having data to show acute myocardial infarction, the degree that various functions index changes and recovers, speed is all relevant to myocardial infarct size, and left ventricle heart infarction scope is larger, and the easypro contracting performance in left room reduces more obvious, and it is poorer to recover.Therefore, at present using reducing myocardial infarction ranges as the curative effect index evaluating medicaments for resisting myocardial ischemia.4. the arrhythmia that compound preparation of the present invention also brings out aconitine has obviously antagonism (P<0.01).This effectively supports the reason of former side for Mongolian medicine's " cardiopalmus disease "; 5. compound preparation of the present invention is to the experimental result of Heart Failure Wistar Rats hemodynamic effects after heart infarction: this agent treatment heart failure and early stage administration have obvious antagonism (P<0.05) to the generation and deterioration that reverse heart failure.6. compound preparation of the present invention on high lipid food feed Corn Bract Decotion affect experimental result: compound preparation group Aortic Plaque area percentage of the present invention is starkly lower than model group (P<0.05), has study of anti-atherogenic effect." conspicuous according to " blood rich syndrome (disease) requirement mutually that to meet the insomnia uncomfortable in chest, dizzy of Mongolian medicine's clinical treatment cardiopalmus be feature.
In the typical case accepted for medical treatment (making a definite diagnosis by national standard) angina pectoris medical record, randomly draw 50 examples, do a small sample statistics as follows.
(1) physical data: male 25 example in 50 examples, women 25 example; At minimum 27 years old of age, maximum 78 years old, within 40 ~ 50 years old, person was in the majority; The most elder of medical history 28 years, the shortest person 10 days.Majority of cases does not have heavier complication.
(2) Therapeutic Method: follow Mongolian medicine's theory, takes compound preparation watered pill 40-60 every day ball of the present invention, and 2 times on the one or serious symptom 3 times, each 20, general surrounding is a course for the treatment of.Above patient medication general 1 ~ 2 course for the treatment of.
(3) criterion of therapeutical effect: angina pectoris is number of times 1.: 0 point: nothing; 2 points: one week less than 6 times; 4 points: one week 7 ~ 21 times; 6 points: one week more than 22 times.2. the persistent period: 0 point: nothing; 2 points: each persistent period≤5 minutes; 4 points: each persistent period > 5 < 10 minutes; 6 points: each persistent period >=10 minutes.3. pain degree: 0 point: nothing; 2 points: pain degree is light, alleviate after having a rest, without nitroglycerin; 4 points: nitroglycerin during morbidity, can normal activity after pain relief; 6 points: number of incidences is many, pain degree weight, perspires, and affects daily life (wear the clothes, have a meal, take a walk, stool waits impact morbidity) with nitroglycerin.4. nitroglycerin consumption: 0 point: nothing; 2 points: one week 1 ~ 4 unit; 4 points: one week 5 ~ 9 unit; More than 6 points: one week 10 unit.Uncomfortable in chest: 0 point: nothing; 2 points: uncomfortable in chest once in a while, spontaneous remission; 4 points: appearance uncomfortable in chest is frequent, but does not affect daily life; 6 points: symptom duration uncomfortable in chest is long, affects daily life.Nervous: 0 point: nothing; 2 points: occur nervous during motion; 4 points: occur during light exercise; 6 points: occur during rest.Breathe hard: 0 point: nothing; 1 point: breathe hard after motion; 2 points: breathe hard after light exercise; 3 points: breathe hard during rest.Weak: 0 point: nothing; 1 point: weak during motion; 2 points: weak after light exercise; 3 points: weak severe symptoms, weak during rest.
Treatment standard rate (n): before (before treatment the rear total score of total score-treatment)/treatment, each case of total score × 100% arranges total score n >=70% is effective by above standard; 70% > n >=30% takes a turn for the better; N < 30% is invalid.
(4) efficacy result: obvious effective rate 70%, takes a turn for the better 26%, invalid 4%; Total effective rate 96%.Illustrate that the party treats angina pectoris and truly has original effect.
Adnexa: model case: patient king ×, man, 48 years old, Inner Mongol private owner, on June 3rd, 2004 main suit: angina pectoris, shoulder pain, cardiopalmus, nervous, dizzy insomnia 4 years; Angina pectoris aggravation in early stage main suit's day, cardiopalmus, the situation such as nervous are made a practice of, and the symptoms such as shoulder pain cause the stiff pain of health, often dizzy, and repeatedly occur that dizziness such as to fall down to the ground at the harsh conditions, sleep therapy underground, long-time sleeping time every day is no more than 4 hours.Treatment take medicament of the present invention, through take medicine one the course for the treatment of symptom obviously alleviate.Continue to take medicine one the course for the treatment of cardiopalmus, the symptom such as nervous, dizzy insomnia disappears substantially, angina pectoris symptom and pain degree disappear substantially, and shoulder pain symptom weakens, and drug withdrawal is followed up a case by regular visits to 1 year, accidental recurrence.
Claims (3)
1. treat a compound Mongolian medicinal preparation for coronary heart disease, it is formed by the preparation of raw material of following weight portion: Fructus Choerospondiatis 7-11, Semen Myristicae 4-8, Lignum Aquilariae Resinatum 4-8; Flos Carthami 2-6, Fructus Tsaoko 2-6, Fructus Gardeniae 1-5; Radix Aucklandiae 3-6, Poria 3-6, Radix Angelicae Sinensis 3-6, Fructus Cumini Cymini 3-6, Stigma Croci 1-2, Resina Ferulae 1, artificial Calculus Bovis 0.5.
2. the compound Mongolian medicinal preparation for the treatment of coronary heart disease according to claim 1, it is formed by the preparation of raw material of following weight portion: Fructus Choerospondiatis 9, Semen Myristicae 6, Lignum Aquilariae Resinatum 6; Flos Carthami 4, Fructus Tsaoko 8, Fructus Gardeniae 3; the Radix Aucklandiae 4.5, Poria 4.5, Radix Angelicae Sinensis 4.5, Fructus Cumini Cymini 4.5, Stigma Croci 1.5, Resina Ferulae 1, artificial Calculus Bovis 0.5.
3. the compound Mongolian medicinal preparation of the treatment coronary heart disease described in claim 1 or 2, wherein said preparation is powder, the watered pill, drop pill, tablet or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310096440.7A CN103142923B (en) | 2013-03-25 | 2013-03-25 | Compound mongolian medicine preparation for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310096440.7A CN103142923B (en) | 2013-03-25 | 2013-03-25 | Compound mongolian medicine preparation for treating coronary heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103142923A CN103142923A (en) | 2013-06-12 |
| CN103142923B true CN103142923B (en) | 2015-01-28 |
Family
ID=48541432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310096440.7A Active CN103142923B (en) | 2013-03-25 | 2013-03-25 | Compound mongolian medicine preparation for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142923B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103385921A (en) * | 2013-08-07 | 2013-11-13 | 王智森 | Pharmaceutical composition for treating coronary heart disease, preparation and preparation method thereof |
| CN111643623B (en) * | 2020-06-12 | 2022-01-04 | 纳顺达来 | Mongolian medicine for treating coronary heart disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011551A (en) * | 2007-02-05 | 2007-08-08 | 赵志强 | Mongol medicine for treating coronary heart disease |
| CN101590152A (en) * | 2008-05-26 | 2009-12-02 | 内蒙古医学院 | The preparation method of Bawei Chenxiang capsule |
-
2013
- 2013-03-25 CN CN201310096440.7A patent/CN103142923B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011551A (en) * | 2007-02-05 | 2007-08-08 | 赵志强 | Mongol medicine for treating coronary heart disease |
| CN101590152A (en) * | 2008-05-26 | 2009-12-02 | 内蒙古医学院 | The preparation method of Bawei Chenxiang capsule |
Non-Patent Citations (2)
| Title |
|---|
| 冠心病的辨证论治;周次清;《山东医药》;19801231(第8期);第34-37页 * |
| 蒙医药治疗心刺痛的临床体会;敖特根;《中国民族民间医药》;20110831(第16期);第3-4页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103142923A (en) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101695328B (en) | Dendrobium tea | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN102772704B (en) | Medicament for treating geriatric disease | |
| CN101537060B (en) | Medicine for treating AIDS | |
| CN103719493B (en) | Siberian solomonseal rhizome health-care tea of a kind of brain-nourishing intelligence-benefiting and preparation method thereof | |
| CN100389802C (en) | Medicine for treating and preventing chronic obstractive pneumonia | |
| CN102631579A (en) | Oral Chinese herbal preparation for treating post-traumatic brain syndrome | |
| CN103142923B (en) | Compound mongolian medicine preparation for treating coronary heart disease | |
| CN103142924B (en) | Mongolian medicine compound preparation for treating coronary heart disease | |
| CN102836267A (en) | Traditional Chinese drug oral liquid for treating children night sweat | |
| CN1124856C (en) | Pill for treating hemiplegia | |
| CN103142925B (en) | A kind of Mongolian compound preparation being used for the treatment of coronary heart disease | |
| CN102266481B (en) | Chinese medicinal preparation for treating chronic cerebral circulation insufficiency | |
| CN102949681B (en) | Composition for preventing or treating colds, and its preparation method | |
| CN101385844B (en) | Traditional Chinese medicine composition for treating the hemorrhoids and preparation method thereof | |
| CN102716448A (en) | Chinese patent medicine and TCM decoction capable of effectively curing nausea and vomiting | |
| CN103041171B (en) | Medicine for treatment of menopause vertigo | |
| CN102552841A (en) | Traditional Chinese medicine for treating apoplexy sequelae | |
| CN102266417B (en) | Chinese medicine for treating acquired immune deficiency syndrome and preparation method and administration method thereof | |
| CN107753775A (en) | A kind of chrysanthemum composition and its application | |
| CN100394937C (en) | Medicine for preventing and treating cardiac and cerebral vascular diseases | |
| CN104906495A (en) | Hypertension symptom improvement medicine mainly using rhodiola rosea | |
| CN105343688A (en) | Medicine composition for treating myocardial infarction and application thereof | |
| CN105362999A (en) | Traditional Chinese medicine preparation for preventing and treating infantile repeated cold and preparation method thereof | |
| CN103239688A (en) | Traditional Chinese medicine for treating coronary heart disease and preparation method of traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |